Duvyzat (Givinostat) is a drug used to treat Duchenne muscular dystrophy (DMD) for patients 6 years and older. The drug is a histone deacetylase (HDAC) inhibitor that slows disease progression by regulating gene expression.
How to use Duvyzat
Correct use of Duvyzat is the key to clarifying the therapeutic effect. The following content will detail its usage and dosage, adverse reaction management, and precautions to help patients use the drug safely.
Usage and Dosage
The recommended dose of Duvyzat is based on the patient's weight and should be taken twice a day with food. The specific dose is as follows: 22.2 mg (about 2.5 ml) per dose for patients weighing 10-20 kg; 31 mg (about 3.5 ml) per dose for patients weighing 20-40 kg; 44.3 mg (about 5 ml) per dose for patients weighing 40-60 kg; 53.2 mg (about 6 ml) per dose for patients weighing 60 kg and above. Shake the bottle thoroughly before administration and use a graduated oral syringe to accurately measure the dose.
Adverse reaction management
Duvyzat may cause adverse reactions such as thrombocytopenia, diarrhea or elevated triglycerides. If these occur, the dose needs to be adjusted according to body weight. For example, the first dose of patients weighing 10-20 kg can be reduced to 17.7 mg, and if symptoms persist, it can be further reduced to 13.3 mg. If the adjustment still fails to relieve symptoms, it is recommended to stop the drug and seek medical attention.
Rational use of Duvyzat requires strict adherence to dosage instructions and timely treatment of adverse reactions. Patients should monitor relevant indicators regularly to ensure drug safety.
How to buy Duvyzat
Duvyzat is not currently available in China, and patients need to purchase it through specific channels. The following content will introduce its manufacturer, price and purchase precautions.
Manufacturer and price
Duvyzat is produced by Italfarmaco S.p.A. in Spain, with a specification of 140ml/box. This drug is an original drug, its price is relatively high, and there are currently no generic drugs on the market.
Purchase precautions
Since Duvyzat is not included in China's medical insurance, patients need to purchase it through overseas channels. When purchasing, you need to pay attention to the authenticity and storage conditions of the drug, and make sure that the drug meets the requirements during transportation. After opening the bottle, it must be used within 60 days, and the unused part should be discarded.
When purchasing Duvyzat, you need to carefully choose the channel and pay attention to the storage and expiration date of the drug. Patients can consult professional medical institutions or pharmacies for more purchase guidance.
Pharmacokinetics of Duvyzat
Understanding the pharmacokinetics of Duvyzat helps optimize the medication regimen. The following content will introduce its absorption characteristics, food effects, and interactions with other drugs.
Absorption and food effects
Duvyzat reaches peak blood concentration about 2-3 hours after oral administration. When taken with a high-fat meal, the drug exposure (AUC) increases by about 40%, the peak concentration (Cmax) increases by 23%, and the peak time is delayed. Therefore, it is recommended to take it with food to enhance the efficacy.
Drug interactions
Duvyzat may interact with other drugs. It is a weak intestinal CYP3A4 inhibitor, which may affect the blood concentration of CYP3A4 sensitive substrates. In addition, it should be avoided to use it with drugs that prolong the QT interval to avoid increasing the risk of arrhythmias.
Understanding the pharmacokinetic characteristics of Duvyzat can help patients better plan medication time and diet, while avoiding potential drug interactions.
